Codelivery of NOD2 and TLR9 Ligands via Nanoengineered Protein Antigen Particles for Improving and Tuning Immune Responses

Vaccine adjuvants that can induce robust protective immunity are highly sought after for the development of safer and more effective vaccines. Vaccine formulation parameters that govern efficacy are still far from clear, such as the diverse impacts of codelivering agonist molecules for innate cell receptors (e.g., pattern recognition receptors). In this study, a mesoporous silica‐templating approach is used to fabricate protein antigen (ovalbumin) particles covalently functionalized with agonists for NOD‐like receptor 2 (NOD2) and Toll‐like receptor 9 (TLR9). Particle‐induced combinatorial NOD2/TLR9 signaling results in synergistic inflammatory cytokine secretion by mouse macrophages (RAW 264.7). Administration of NOD2/TLR9 particles in mice results in adaptive immune responses that are both quantitatively and qualitatively different than those resulting from administration of particles conjugated with either NOD2 or TLR9 agonists alone. While delivery of NOD2 agonists alone activates T helper 2 (Th2)‐type responses (and no CD8+ T cell activation) and delivery of TLR9 agonists alone activates CD8+ T cell and T helper 1 (Th1)‐type responses, codelivery of NOD2 and TLR9 agonists enhances Th1‐type responses and abrogates CD8+ T cell activation. The results illustrate that in the particle‐based system, NOD2 activation plays different roles in polarizing adaptive immune responses depending on coactivation of TLR9.